Kate Madigan, MD, currently serves as the Chief Medical Officer at Hemab Therapeutics since January 2025, following a tenure in the same role at Syndax Pharmaceuticals from March 2022 to January 2025. With extensive expertise in clinical development, Madigan held the position of Vice President, Head of Clinical Development at Syros Pharmaceuticals from June 2019 to January 2022 and previously worked as Senior Medical Director and Medical Director in Clinical Research at Alnylam Pharmaceuticals. Early career roles included Medical Director at Biogen, where responsibilities included leading initiatives within the Rare Disease Innovation Unit and hematology clinical development. In academia, Madigan served as Associate Professor and Assistant Professor of Pediatrics at UCSD/Rady Children's Hospital San Diego, focusing on pediatric hematology/oncology, alongside teaching responsibilities at the UCSD School of Medicine. Madigan holds a Doctor of Medicine (M.D.) from the Keck School of Medicine of the University of Southern California and a Bachelor’s Degree from Dartmouth College.
This person is not in any teams
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.